This disclosure generally relates to treating anemias. More specifically, the disclosure relates to use of muscarinic acetylcholine receptor subtype 4 antagonists, such as small molecule compounds, to promote self-renewal of burst forming unit erythroid (BFU-E) cells and treat anemias.
这项披露通常涉及治疗贫血。更具体地,该披露涉及使用肌效
胆碱受体亚型4拮抗剂,如
小分子化合物,促进爆发形成单位红细胞(BFU-E)细胞的自我更新并治疗贫血。